Related Experiment Video

Updated: Aug 29, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Antiangiogenic therapy

Daniel Albo1, Thomas N Wang, George P Tuszynski

  • 1Department of Surgery, Section of Surgical Oncology, Medical College of Georgia, Augusta, GA 30912, USA.

Current Pharmaceutical Design
|February 3, 2004
PubMed

Insights

Antiangiogenic agents target tumor blood vessel formation, offering a novel cancer treatment. While promising due to fewer side effects and broader applicability, clinical trial challenges remain.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis.
  • The "angiogenic switch" enables tumor cells to invade surrounding tissues and spread.
  • Antiangiogenic agents represent a targeted approach to cancer therapy.

Purpose of the Study:

  • To review current antiangiogenic agents and their role in cancer treatment.
  • To discuss the advantages of antiangiogenic therapy over traditional chemotherapy.
  • To explore challenges and future directions in clinical antiangiogenic drug development.

Main Methods:

  • Review of scientific literature on angiogenesis and antiangiogenic agents.
  • Analysis of theoretical benefits and potential toxicities of antiangiogenic drugs.
  • Examination of ongoing clinical trials and their implications.

Main Results:

  • Antiangiogenic agents target tumor endothelial cells, potentially bypassing resistance mechanisms.
  • These agents may offer reduced toxicity compared to standard chemotherapy, avoiding cytopenias.
  • Potential for broad applicability across various tumor types, independent of cell characteristics.

Conclusions:

  • Antiangiogenic therapy holds significant promise for cancer treatment and prevention.
  • Overcoming obstacles in clinical trials is crucial for accurately assessing efficacy.
  • Further research and development are needed to fully realize the potential of antiangiogenic drugs.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...